<SEC-DOCUMENT>0001104659-24-065178.txt : 20240910
<SEC-HEADER>0001104659-24-065178.hdr.sgml : 20240910
<ACCEPTANCE-DATETIME>20240524170224
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-24-065178
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACTUATE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001652935
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473044785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1751 RIVER RUN
		STREET 2:		SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
		BUSINESS PHONE:		847-986-4190

	MAIL ADDRESS:	
		STREET 1:		1751 RIVER RUN
		STREET 2:		SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apotheca Therapeutics, Inc.
		DATE OF NAME CHANGE:	20150911
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">May&nbsp;24, 2024</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;<IMG SRC="tm247121d14_correspimg001.jpg" ALT=""></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 75%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 13%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 10pt">&#8239;Janet Spreen<BR>
    &#8239;direct dial: 216.861.7090<BR> &#8239;jspreen@bakerlaw.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office of Life
    Sciences<BR>
    Division of Corporate Finance<BR>
    Securities and Exchange Commission<BR>
    100 F Street, N.E.<BR>
    Washington, D.C. 20549<BR>
    Attn: Eric Atallah, Kevin Kuhar, Jessica <BR>
    Dickerson and Tim Buchmiller</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Re:</B></FONT></TD><TD><B>Actuate
                                            Therapeutics,&nbsp;Inc. Amendment No.&nbsp;3 Draft Registration Statement on Form&nbsp;S-1
                                            Submitted May&nbsp;13, 2024 (the &ldquo;Draft Registration Statement&rdquo;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of Actuate Therapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;),
we hereby respond as set forth below to the letter dated May&nbsp;20, 2024 from the staff of the U.S. Securities and Exchange Commission
(the &ldquo;Staff&rdquo;) with respect to the above-referenced confidential draft Amendment No.&nbsp;3 to Draft Registration Statement.
Simultaneously with the submission of this letter, the Company is publicly filing via EDGAR a Registration Statement on Form&nbsp;S-1
(the &ldquo;Registration Statement&rdquo;) responding to the Staff&rsquo;s comments and updating its disclosures in the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To assist your review, we have retyped the text of the Staff&rsquo;s
comments in italics below. Please note that all references to page&nbsp;numbers in our responses refer to the page&nbsp;numbers of the
Registration Statement. Capitalized terms used in our responses below that are not otherwise defined have the meanings ascribed to them
in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Developing Elraglusib for the Treatment of Ewing Sarcoma Development
Plan in Ewing Sarcoma, page&nbsp;125</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d14_correspimg002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May&nbsp;24, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <I>We note your response to prior comment 1, and we reissue the
comment in part. Please further revise the added disclosure in the first paragraph of this section to clarify whether any action on the
amended 1902 Phase 1/2 protocol will be required by the FDA. Please also clarify the status and timing for the planned amendment, including
for your central IRB approval and, if applicable, any other required regulatory approvals.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company has
revised its disclosure on page&nbsp;125 to clarify whether any action on the amended 1902 Phase 1/2 protocol will be required by the
FDA and also clarify the status and timing for the planned amendment, including for the Company&rsquo;s central IRB approval and, if
applicable, any other required regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Janet Spreen</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.75pt; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></TD>
    <TD STYLE="padding-right: 5.75pt; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm247121d14_correspimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d14_correspimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "# *@# 2(  A$! Q$!_\0
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MZ&H_[0T%X%O?MFFM$C86?S4*J0.S9X(% ')S:I=:7:WEU;QQ^:+R\;YT#;,
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MO7YA@>E7OL=M]G-O]GA\D]8]@VG\.E &?X<93I3")MT"7$Z0$-N'EB1@N#Z
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6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm247121d14_correspimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d14_correspimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N GL# 2(  A$! Q$!_\0
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M\B/SH GHIID0,%+J&)P!GFH8[VUE\W9/&1"_ER'=PK8!Q^HH L44 @C(Y%%
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M\U8XYI))8$)!52NU@#VY<?5: $ET34I!?VZ2;8D5WM)"_P S2O$%R?3!W?\
M?7M4">'[QFC81!8UDB;RWV@'R@[*3M']\I^5:DVN%-0VJ4:V$@5C@Y4")I&/
MZH/QJ9/$-G(& 6;S RJ(MGS,6!(P/HI_*@#GX]!U&>Z\N6$1VIABC/(!/[T-
M)G Y^5 !GU-:;Z3+%?O*+19;0W#2"!3CGRT56Q]0_P"8J:+Q)#ON#,CJ!,T4
M,>WYVVJI<D>S'%">)K:6YC\H/-;SQQ&$QH2S,P=B,>RH#^- %K0;%]/TE89(
MUCD:225D4Y"EW9L ^V<?A6G6'<>(X8I;<I'*T;).\P"99!&0IR/J?TJ>76X8
M;N1#N= $ 5%R=Q!8_AMV_G0!JUSVFVFH6%BNF?9(6 E8O.S95T+$DD?WB#T]
M:V[2ZCO;.&ZA),4R!T)&.",BIJ .6ETN_*-Y5LBW4<T\PN2_+DA]BCV^91[
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M[!-<Z+<6\$?F/* C+G&4+ -_X[FLO5+74]1(GCM%C2.-H?+=_F=79=Y]L*O
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M%:=EH;P7%M<-&OGM>S7,[DY.&#A5_)E_*KW]N6HD 995C+M'YI3Y-R@DC/\
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MUVA@SMG;TP=Y&/85NT4 8DWAU)K06YN-JMO\S;&H#;NX'\)'0'M6V.!BBB@
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:M/CLI;R5&+/=3F:0GUVA0/P"@5;HHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
